Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market after reporting positive results in a phase 2 trial. The US biotech’s ...

Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving ...

Catalyst Biosciences is a research and clinical development biopharmaceutical company focusing on rare disorders of the complement or coagulation systems. Catalyst’s approach builds on the ...

Bright Minds Biosciences has a decent balance sheet, with roughly $40.3 million in cash. Click here to find out why I rate ...